- Amorepacific Holdings’ operating profit for Q2 reached 80.12 billion won, a significant increase from 12.22 billion won the previous year, but fell short of the estimated 86.64 billion won.
- Net profit was 24.97 billion won, marking a sharp decline of 87% compared to the same period last year.
- Sales totaled 1.09 trillion won, showing an 8.9% increase year-on-year, although slightly below the estimated 1.11 trillion won.
- Amorepacific’s shares decreased by 4.8%, closing at 29,550 won with a trading volume of 109,702 shares.
- Analyst ratings included five buy recommendations, no holds, and one sell.
A look at Amorepacific Corporation Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Amorepacific Corporation, a global leader in skincare and beauty products, has received a positive outlook based on its Smartkarma Smart Scores. With a top score in Growth and Momentum, the company is positioned for long-term success. Its innovative product development and robust market presence contribute to its strong Growth score. Additionally, its Resilience score indicates a stable foundation to weather market fluctuations. Although the Dividend score is not as high, Amorepacific’s focus on growth and momentum signals a promising future for the company.
Amorepacific Corporation develops, manufactures, and exports a wide range of beauty, skincare, and health products globally. The company’s commitment to quality and innovation has been recognized through its high scores in Growth and Momentum, showcasing its potential for continued success in the industry. Despite a slightly lower score in Dividend, the company’s diverse product portfolio and strong market presence position it well for long-term growth and sustainability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
